Additionally, inhibiting the CD80-CD28-mediated signaling pathway via specific RNAi and antibodies to block the interaction between CD28 and B7 reduced immune cell activation and reversed the damage in a pathological lupus nephritis model (66). This evidence concerns the gene CD80 and lupus nephritis.